Overview

Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma

Status:
Terminated

Trial end date:
2020-05-01

Target enrollment:

Participant gender:

Summary

The purpose of this trial is to determine the benefit of the combination of nab-paclitaxel plus gemcitabine given for 6 cycles, followed by maintenance nab-paclitaxel alone, in patients with cisplatin-ineligible or cisplatin-incurable advanced urothelial carcinoma (UC).

Phase:

Phase 2

Details

Lead Sponsor:

SCRI Development Innovations, LLC

Collaborator:

Celgene

Treatments:

Albumin-Bound Paclitaxel
Cisplatin
Gemcitabine
Paclitaxel